TEOXANE announces FDA approval for three HA dermal fillers, RHA®2, RHA®3 and RHA®4 indicated for the correction of moderate to severe dynamic facial wrinkles and folds.
Teoxane Laboratories, a global leader in Hyaluronic Acid dermal fillers, are pleased to announce that it has received US Food and Drug Administration (FDA) approval for 3 HA dermal fillers, RHA®2, RHA®3 and RHA®4 for the correction of moderate to severe dynamic facial wrinkles and folds (NLF) in adults aged 22 years or older.
Teoxane’s Founder and CEO Mrs Valerie Taupin said: “Since its inception in 2003, the foundations of the company have been based on integrated Research & Development. Today we are delighted with the news of the FDA approval of RHA®2, RHA®3 and RHA®4 for sale in the US market. This further reinforces our commitment to delivering science-based, high-quality HA dermal fillers to the global market”.
We are ever thankful for your continued loyalty to the Teoxane brand and we are delighted that this news will help to further strengthen the positioning of Teoxane as a world class HA provider in today’s aesthetic market.